| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/21/2007 | EP1753765A1 Immuno inhibitory heterocyclic compounds |
| 02/21/2007 | EP1753764A1 Pyrrolopyridine derivatives |
| 02/21/2007 | EP1753763A2 Indazole and indolone derivatives and their use as pharmaceuticals |
| 02/21/2007 | EP1753762A1 Lewis acid mediated synthesis of cyclic esters |
| 02/21/2007 | EP1753761A2 Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof |
| 02/21/2007 | EP1753760A1 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
| 02/21/2007 | EP1753758A1 Mercaptoimidazoles as ccr2 receptor antagonists |
| 02/21/2007 | EP1753757A1 Substituted 2,5-diaminomethyl-1h-pyrroles |
| 02/21/2007 | EP1753756A1 3-¬4-(6-{4,5-dihydroisoxazol-3-yl}pyridin-3-yl)-3-phenyl|-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents |
| 02/21/2007 | EP1753755A1 3- {4- (pyridin-3-yl) phenyl} -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents |
| 02/21/2007 | EP1753754A1 3- '4- {6-substituted alkanoyl) pyridin-3-yl} -3-phenyl! -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents |
| 02/21/2007 | EP1753753A1 3-(4-(2-dihydroisoxazol-3-ylpyrdin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections |
| 02/21/2007 | EP1753752A1 Highly selective novel amidation method |
| 02/21/2007 | EP1753750A1 Thiophene heteroaryl amines |
| 02/21/2007 | EP1753749A1 Novel indole derivatives as selective androgen receptor modulators (sarms) |
| 02/21/2007 | EP1753747A1 5,6-diphenyl-1,2,4-triazinic dimeric derivatives and the use thereof in the form of sun-protective agents |
| 02/21/2007 | EP1753746A2 Novel pyrrole derivatives with angiotensin ii antagonist activity |
| 02/21/2007 | EP1753745A2 Pyrazinylmethyl lactam derivatives |
| 02/21/2007 | EP1753744A1 Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
| 02/21/2007 | EP1753743A1 Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| 02/21/2007 | EP1753742A2 Magnesium complexes of s-omeprazole |
| 02/21/2007 | EP1753741A1 Crystalline forms of (+) and (-)-erythro-mefloquine hydrochloride |
| 02/21/2007 | EP1753740A2 Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| 02/21/2007 | EP1753739A1 Imidazol-2-one compounds useful in the treatment of various disorders |
| 02/21/2007 | EP1753738A1 Pyrrole compounds as inibitors of erk protein kinase, synthesis thereof and intermediates thereto |
| 02/21/2007 | EP1753736A2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/21/2007 | EP1753735A1 Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| 02/21/2007 | EP1753734A1 Nitric oxide donors and uses thereof |
| 02/21/2007 | EP1753733A1 Small molecules for treatment of hypercholesterolemia and related diseases |
| 02/21/2007 | EP1753732A1 Phenyl-sulfamates as aromatase inhibitors |
| 02/21/2007 | EP1753731A2 Pyrimidin-4-one derivatives and their use as p38 kinase modulators |
| 02/21/2007 | EP1753730A1 Dipeptidyl peptidase inhibitors |
| 02/21/2007 | EP1753729A1 Novel imidazole derivatives, the production thereof, and the use of the same as intermediate products for producing medicaments and pesticides |
| 02/21/2007 | EP1753727A1 Novel cis-imidazolines |
| 02/21/2007 | EP1753725A1 Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics |
| 02/21/2007 | EP1753724A1 Heterocyclic derivatives for treatment of hyperlipidemia and related diseases |
| 02/21/2007 | EP1753723A1 Substituted quinoline derivatives as mitotic kinesin inhibitors |
| 02/21/2007 | EP1753722A2 Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
| 02/21/2007 | EP1753721A1 Aroyl-o-piperidine derivatives for the treatment of diabetes-related problems |
| 02/21/2007 | EP1753719A1 Substituted pyrrolidine-2-ones |
| 02/21/2007 | EP1753718A1 3-amino-2-phenylpyrrolidine derivatives |
| 02/21/2007 | EP1753716A1 Basic salts and monohydrates of certain alpha, beta-proprionic acid derivative |
| 02/21/2007 | EP1753714A2 2-substituted and 4-substituted aryl nitrone compouds |
| 02/21/2007 | EP1753713A2 Synthesis of tetracyclines and analogues thereof |
| 02/21/2007 | EP1753712A1 Amino-propanol derivatives |
| 02/21/2007 | EP1753512A2 Tetrahydropyridothiophenes |
| 02/21/2007 | EP1753511A2 Treating depressive disorders with carbonic anhydrase activators |
| 02/21/2007 | EP1753507A1 Combination of radio waves and pharmacologically active substances |
| 02/21/2007 | EP1753468A2 Carboranylporphyrins and uses thereof |
| 02/21/2007 | EP1753464A2 Annexin ii and uses thereof |
| 02/21/2007 | EP1753461A1 Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide |
| 02/21/2007 | EP1753460A2 Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| 02/21/2007 | EP1753459A2 Composition and method for improving pancreatic islet cell survival |
| 02/21/2007 | EP1753457A2 Cationic bacteriochlorophyll derivatives and uses thereof |
| 02/21/2007 | EP1753456A2 Methods for treating conditions associated with masp-2 dependent complement activation |
| 02/21/2007 | EP1753444A1 Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit |
| 02/21/2007 | EP1753436A2 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle |
| 02/21/2007 | EP1753435A1 Use of a combination of ethinyl estradiol and chlormadinone acetate for the production of a medicament |
| 02/21/2007 | EP1753434A2 Enhanced bimatoprost ophthalmic solution |
| 02/21/2007 | EP1753433A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and pde v inhibitors |
| 02/21/2007 | EP1753432A1 Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction |
| 02/21/2007 | EP1753431A1 Pharmaceutical compositions comprising zd6474 |
| 02/21/2007 | EP1753430A2 Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders |
| 02/21/2007 | EP1753429A1 Modulators of muscarinic receptors |
| 02/21/2007 | EP1753428A2 Kinase inhibitors as therapeutic agents |
| 02/21/2007 | EP1753427A1 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| 02/21/2007 | EP1753426A2 Ruminant treatments |
| 02/21/2007 | EP1753425A1 A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer |
| 02/21/2007 | EP1753423A2 Benzoureas having anti-diabetic activity |
| 02/21/2007 | EP1753422A2 Small molecule inhibitors for mrp1 and other multidrug transporters |
| 02/21/2007 | EP1753421A2 Arylsulfonamides and uses as hydroxysteroid dehydrogenase |
| 02/21/2007 | EP1753420A1 Indole derivatives useful for treating resistance to antitumour agents |
| 02/21/2007 | EP1753419A1 Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities |
| 02/21/2007 | EP1753418A2 Compositions comprising nebivolol |
| 02/21/2007 | EP1753417A2 Selective androgen receptor modulators and methods of use thereof |
| 02/21/2007 | EP1753416A2 Anti-retroviral moronic acid derivatives |
| 02/21/2007 | EP1753415A2 Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| 02/21/2007 | EP1753414A1 Novel use of peptide compounds for treating dyskinesia |
| 02/21/2007 | EP1753413A2 Novel medical uses of compounds showing cb sb 1/sb -antagonistic activity and combination treatment involving said compounds |
| 02/21/2007 | EP1753412A1 Self-heating pharmaceutical patch |
| 02/21/2007 | EP1753409A2 Dosage form containing the active ingredient cholylsarcosine |
| 02/21/2007 | EP1753408A1 Hormonal contraceptive containing a combination of ethinyl estradiol and chlormadinone acetate |
| 02/21/2007 | EP1753407A2 Sugar coatings and methods therefor |
| 02/21/2007 | EP1753406A1 Coated tablet formulation and method |
| 02/21/2007 | EP1753401A1 Rapidly soluble granulate of bromohexine or bromohexine hydrochloride, method for the production of said granulate and the use thereof |
| 02/21/2007 | EP1753400A2 Ziprasidone dosage form |
| 02/21/2007 | EP1753397A2 Galantamine salts, method of producing it and nasal composition thereof |
| 02/21/2007 | EP1753380A2 Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
| 02/21/2007 | EP1753309A1 Food compositions containing creatine |
| 02/21/2007 | EP1753305A1 Liquid nutritional supplement and method for preparing same |
| 02/21/2007 | EP1753292A2 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF PRIMATE POLYOMAVIRUS GENES |
| 02/21/2007 | EP1753289A1 Antimicrobial composition |
| 02/21/2007 | EP1682129B1 N-thiazol-2-yl-benzamide derivatives |
| 02/21/2007 | EP1608685B1 Vegf antagonists for the treatment of diabetes |
| 02/21/2007 | EP1608362B1 Stabilized pharmaceutical preparation comprising an amorphous active substance |
| 02/21/2007 | EP1581517B1 Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 02/21/2007 | EP1569924A4 Nf-kb inhibitors |
| 02/21/2007 | EP1567488B1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease |
| 02/21/2007 | EP1551798B1 Novel sulphones for inhibition of gamma secretase |
| 02/21/2007 | EP1545757B1 Perfluorocarbon emulsions with non-fluorinated surfactants |